Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Basal Insulin, Bolus Insulin, DPP-IVi, Glucose Monitoring, Other

April 29, 2021

Dexcom, Teladoc, Amarin, Biocon, and Merck Q1 '21 Earnings Updates; Abbott Libre 3 User Reviews

Here is a brief preview of this blast: Six cardiometabolic-related news items have recently been observed from Dexcom, Abbott, Teladoc, Amarin, Biocon, and Merck. Below, FENIX provides highlights and insights for the respective news items.